Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,808
Total Claims
$723K
Drug Cost
366
Beneficiaries
$1,975
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+37%
Opioid rate vs peers
3.5% vs 2.6% avg
+85%
Cost per patient vs peers
$1,975 vs $1,068 avg
+66%
Brand preference vs peers
14.9% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
3.5%
Opioid Rate
311
Opioid Claims
$8,099
Opioid Cost
7.7%
Long-Acting Rate
Brand vs Generic
Brand: 1,298 claims · $552K
Generic: 7,412 claims · $165K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 79 | $84K |
| Apixaban | 164 | $71K |
| Sitagliptin Phosphate | 43 | $29K |
| Dapagliflozin Propanediol | 15 | $23K |
| Mirabegron | 28 | $17K |
| Rivaroxaban | 50 | $17K |
| Empagliflozin | 20 | $16K |
| Rimegepant Sulfate | 12 | $15K |
| Semaglutide | 15 | $15K |
| Insulin Detemir | 46 | $15K |
| Fluticasone/Umeclidin/Vilanter | 21 | $14K |
| Tirzepatide | 13 | $14K |
| Sitagliptin Phos/Metformin Hcl | 30 | $14K |
| Insulin Aspart | 21 | $13K |
| Empagliflozin/Linagliptin | 21 | $12K |
Prescribing Profile
Patient Profile
70
Avg Age
69%
Female
1.33
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About